1-Methyl-DMT, or 1-Me-DMT, also known as 1-methyl-N,N-dimethyltryptamine or as 1,N,N-trimethyltryptamine (1,N,N-TMT or 1-TMT), is a serotonin receptor modulator of the tryptamine family related to dimethyltryptamine (DMT) and lespedamine (1-methoxy-DMT).
1-Methyl-DMT appears to have similar affinity for serotonin receptors as DMT, but is more toxic than DMT in rodents. In another study, it showed 3-fold higher affinity for the serotonin 5-HT<sub>2A</sub> receptor than DMT. In a further study, it showed abolished affinity for the 5-HT<sub>1E</sub> receptor and 30-fold lower affinity for the serotonin 5-HT<sub>1F</sub> receptor than DMT. 1-Methyl-DMT shows comparable psychoplastogenic effects in preclinical research to DMT.
The chemical synthesis of 1-methyl-DMT has been described.
Analogues of 1-methyl-DMT include dimethyltryptamine (DMT), 1-methyltryptamine, lespedamine (1-MeO-DMT), 1-methylpsilocin (1-Me-4-HO-DMT; CMY-16), 2-methyl-DMT, 4-methyl-DMT, 5-methyl-DMT, 6-methyl-DMT, and 7-methyl-DMT, among others.
The drug was briefly mentioned by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). 1-Methyl-DMT was first described in the scientific literature by Richard Glennon and colleagues in 1979.